Diseases / Hypertriglyceridemia
Hypertriglyceridemia
DiseaseHypertriglyceridemia is an elevation of blood triglyceride levels that can increase risk of atherosclerotic cardiovascular disease and, at very high levels, acute pancreatitis.
- Trials
- 313
- Recruiting
- 20
- Completed
- 212
- With results
- 70
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Approved for marketing | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 2 | 1 | — | — | 1 | — | — | — | — | — | — | 4 |
| Phase 1 | 2 | 1 | — | 1 | 21 | 2 | 1 | — | 1 | — | — | 29 |
| Phase 1/2 | 1 | — | — | 1 | 7 | — | — | — | — | — | — | 9 |
| Phase 2 | 4 | — | — | 3 | 44 | 8 | 1 | 1 | 1 | — | — | 62 |
| Phase 2/3 | — | — | — | — | 7 | — | — | — | 1 | — | — | 8 |
| Phase 3 | 3 | 2 | — | 5 | 36 | 1 | 3 | — | 3 | — | — | 53 |
| Phase 4 | — | 2 | — | — | 20 | — | 2 | 1 | 9 | — | — | 34 |
| Not applicable | 4 | 2 | 1 | 5 | 59 | 4 | 1 | — | 12 | — | — | 88 |
| Unknown | 4 | 1 | — | — | 17 | 1 | — | — | 1 | 1 | 1 | 26 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hypertriglyceridemia | 4 | 29 | 9 | 62 | 8 | 53 | 34 | 88 | 26 | 313 |
| Dyslipidemias | — | 5 | — | 9 | 3 | 12 | 3 | 8 | 3 | 43 |
| Hypercholesterolemia | — | 2 | 2 | 6 | 1 | 5 | 4 | 11 | 2 | 33 |
| Hyperlipidemias | — | 3 | — | 5 | 3 | 11 | 2 | 7 | — | 31 |
| Insulin Resistance | — | — | — | 2 | 1 | 2 | 8 | 12 | 3 | 28 |
| Obesity | — | 1 | — | 1 | 1 | 2 | 1 | 18 | 3 | 27 |
| Cardiovascular Diseases | — | 2 | — | 2 | — | 3 | 3 | 7 | 7 | 24 |
| Diabetes Mellitus | — | 1 | — | 6 | — | 3 | 2 | 10 | 2 | 24 |
| Metabolic Syndrome | — | — | — | 2 | 1 | 1 | 2 | 13 | 3 | 22 |
| Diabetes Mellitus, Type 2 | — | 1 | — | 3 | 1 | 2 | 6 | 4 | 2 | 19 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | AstraZeneca | 12 | 5 |
| 2 | Ionis Pharmaceuticals, Inc. | 10 | 5 |
| 3 | Arrowhead Pharmaceuticals | 8 | 5 |
| 4 | GlaxoSmithKline | 7 | 3 |
| 5 | Essentialis, Inc. | 6 | 1 |
| 6 | Abbott | 5 | 1 |
| 7 | National Heart, Lung, and Blood Institute (NHLBI) | 5 | 0 |
| 8 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 5 | 1 |
| 9 | Novartis Pharmaceuticals | 5 | 0 |
| 10 | Regeneron Pharmaceuticals | 5 | 1 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Omacor | 28 |
| 2 | Fenofibrate | 26 |
| 3 | eicosapentaenoic acid ethyl ester | 15 |
| 4 | Fish Oils | 8 |
| 5 | Atorvastatin | 6 |
| 6 | Corn Oil | 6 |
| 7 | Diet | 6 |
| 8 | metreleptin | 6 |
| 9 | Fatty Acids, Omega-3 | 5 |
| 10 | Niacin | 5 |
Evidence
- Results reported
- 33%70 of 212 completed
- Published
- 9.4%20 of 212 completed
- Primary endpoint met
- 66.2%49 of 74 analyses
- Median months to report
- 17.5
Documents disclosed
Trial profile
- Median enrollment
- 62
- Median duration
- 22months
- Countries
- 60
- Study sites
- 4330
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 15
- Phase 1
- 48
- Phase 1/2
- 48
- Phase 2
- 56
- Phase 2/3
- 83
- Phase 3
- 311
- Phase 4
- 70
- Not applicable
- 43
- Unknown
- 150
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Houston | United States | 36 |
| 2 | Cincinnati | United States | 31 |
| 3 | Louisville | United States | 29 |
| 4 | Miami | United States | 28 |
| 5 | San Antonio | United States | 26 |
| 6 | Chicoutimi | Canada | 25 |
| 7 | Québec | Canada | 25 |
| 8 | Philadelphia | United States | 24 |
| 9 | St Louis | United States | 23 |
| 10 | Baltimore | United States | 22 |
Terminations
- Terminated
- 16
- Withdrawn
- 8
- Suspended
- 2
- Stopped for recruitment
- 1.6%5 of 313 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT01527747 Suspended | Suspended | Funding | 2024-12-31 |
| NCT03097107 Suspended | Suspended | Management decision to suspend the study due to recruitment issues | 2024-01-31 |
| NCT05609825 Terminated | Terminated | The study was terminated due to a change in risk/benefit ratio, which no longer favoured continued development. | 2024-01-10 |
| NCT04863014 Terminated | Terminated | Sponsor Decision | 2023-02-15 |
| NCT04419688 Terminated | Terminated | recruitment failure | 2022-12-23 |
| NCT04662528 Withdrawn | Withdrawn | suspended | 2022-10-31 |
| NCT04365400 Terminated | Terminated | Trial prematurely terminated on 03 May 2022 due to the results from an interim analysis indicating a lack of efficacy in the study population. | 2022-05-03 |
| NCT05787457 Terminated | Terminated | Insufficient recruitment | 2021-09-30 |
| NCT04088240 Terminated | Terminated | Supplements Expired | 2021-01-31 |
| NCT03729934 Withdrawn | Withdrawn | Dissertation for student changed. | 2021-01-01 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above:
Search all Hypertriglyceridemia trials on ClinicalTrials.gov →